<DOC>
	<DOCNO>NCT00508820</DOCNO>
	<brief_summary>This protocol provide open label romiplostim adult thrombocytopenic subject . Romiplostim administer subcutaneous injection per week . Dose adjustment base platelet count , allow throughout duration study . Rescue therapy allow time study . Reductions concurrent ITP therapy may occur time platelet count &gt; 50,000 .</brief_summary>
	<brief_title>An Open Label Study Romiplostim Adult Thrombocytopenic Subjects With ITP</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Subject ≥ 18 year age Subject diagnosis immune ( idiopathic ) thrombocytopenic purpura per American Society Hematology guideline If Subject &gt; 60 year age , subject write bone marrow aspiration and/or biopsy report consistent diagnosis ITP Subject receive least 1 prior therapy ITP Subject 's platelet count ≤ 30,000 subject experience bleeding uncontrolled conventional therapy Subject ( legallyacceptable representative ) willing able provide write informed consent Subject history hematological malignancy , myeloproliferative disorder , myelodysplastic syndrome ( MDS ) , bone marrow stem cell disorder Subject participate study evaluate PEGrHuMGDF , recombinant human thrombopoietin ( rHuTPO ) , related platelet product Subject know hypersensitivity recombinant E coliderived product Subject receive therapeutic drug device approve local regulatory health agency indication within 4 week Screening Subject reproductive potential use adequate contraceptive precaution , judgment investigator Subject pregnant breast feed Investigator concern regard subject 's ability comply protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Platelet</keyword>
	<keyword>AMG 531</keyword>
	<keyword>Thrombopoietin</keyword>
	<keyword>blood disorder</keyword>
	<keyword>bleed disorder</keyword>
	<keyword>immune thrombocytopenic purpura</keyword>
	<keyword>idiopathic thrombocytopenic purpura</keyword>
	<keyword>immune ( idiopathic ) thrombocytopenic purpura</keyword>
	<keyword>TPO</keyword>
	<keyword>thrombopoietic protein</keyword>
</DOC>